Effects of DHA-NAT on Postprandial Lipidaemia in Healthy Male Subjects

Study acronym: FEAST
StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Study completion date changed from estimate of Apr 1, 2025 to Oct 31, 2023
    • Eligibility criteria expanded, about 6 words
  2. Study completion date: Apr 1, 2024 to Apr 1, 2025v3
  3. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Dec 31, 2023 to Oct 31, 2023
    • Site details revised
    v2
  4. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is an investigator-initiated, randomised, double-blind, placebo-controlled, cross-over human trial investigating the effect of DHA-NAT (C22:6 N-acyl taurine, an endogenous metabolite derived from the omega-3 fatty acid, docosahexaenoic acid) on postprandial plasma triglyceride levels following a high-fat meal.
Trial Details
NCT Number NCT05953064
Lead Sponsor University Hospital, Gentofte, Copenhagen
Conditions
(from sponsor)		 Hypertriglyceridemia
Related terms Hypertriglyceridemia
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov